Back to Search
Start Over
Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia
- Source :
- Clinical Immunology Communications, Vol 1, Iss , Pp 35-44 (2021)
- Publication Year :
- 2021
- Publisher :
- Elsevier, 2021.
-
Abstract
- Human telomerase reverse transcriptase (hTERT) is broadly expressed in many cancers. High hTERT expression have been described in chronic lymphocytic leukemia (CLL). Here we investigated the relationship between anti-hTERT immunity and disease progression in 49 CLL patients. Anti-hTERT T cell responses were evaluated by IFNγ-ELISpot. Complementary flow cytometry analyses were performed, and data were analyzed in regards of the treatment received by CLL patients afterward and disease progression. Anti-hTERT responses were more frequently observed in non-progressive watch and wait patients, and in progressive patients scheduled to receive ibrutinib, as compared to patients scheduled to receive other types of treatment. In vitro, addition of the anti-PD-1 antibody nivolumab increased anti-hTERT responses. Importantly, Kaplan Meier analyses showed significantly longer progression-free survival in patients with anti-hTERT immune responses at diagnosis as compared to non-responder patients. Our results show that anti-hTERT T cell responses represent a new potential biomarker predictive of CLL clinical outcome.
Details
- Language :
- English
- ISSN :
- 27726134
- Volume :
- 1
- Issue :
- 35-44
- Database :
- Directory of Open Access Journals
- Journal :
- Clinical Immunology Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.20171fe6484d48c7bf25ab7d867a845a
- Document Type :
- article
- Full Text :
- https://doi.org/10.1016/j.clicom.2021.11.002